Juan Andres - 01 Mar 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
01 Mar 2022
Net transactions value
-$271,560
Form type
4
Filing time
03 Mar 2022, 15:53:19 UTC
Previous filing
02 Mar 2022
Next filing
15 Mar 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $28,440 +2,000 +22% $14.22* 11,069 02 Mar 2022 Direct F1
transaction MRNA Common Stock Sale $300,000 -2,000 -18% $150.00 9,069 02 Mar 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +32,525 $0.000000 32,525 01 Mar 2022 Common Stock 32,525 $149.52 Direct F2
transaction MRNA Restricted Stock Units Award $0 +8,019 $0.000000 8,019 01 Mar 2022 Common Stock 8,019 $0.000000 Direct F3
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -2,000 -9.7% $0.000000 18,629 02 Mar 2022 Common Stock 2,000 $14.22 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021.
F2 25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F3 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F4 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer